SG Americas Securities LLC Grows Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)

SG Americas Securities LLC raised its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 2,159.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 430,051 shares of the company's stock after purchasing an additional 411,015 shares during the quarter. SG Americas Securities LLC owned 0.38% of Dyne Therapeutics worth $4,498,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Legato Capital Management LLC purchased a new position in Dyne Therapeutics in the 4th quarter worth approximately $305,000. Rhumbline Advisers lifted its holdings in shares of Dyne Therapeutics by 3.0% in the fourth quarter. Rhumbline Advisers now owns 128,244 shares of the company's stock worth $3,021,000 after buying an additional 3,734 shares in the last quarter. Handelsbanken Fonder AB lifted its holdings in shares of Dyne Therapeutics by 16.6% in the fourth quarter. Handelsbanken Fonder AB now owns 22,500 shares of the company's stock worth $530,000 after buying an additional 3,200 shares in the last quarter. Arcadia Investment Management Corp MI lifted its holdings in shares of Dyne Therapeutics by 16.4% in the fourth quarter. Arcadia Investment Management Corp MI now owns 44,940 shares of the company's stock worth $1,059,000 after buying an additional 6,326 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Dyne Therapeutics by 0.3% in the fourth quarter. Bank of New York Mellon Corp now owns 234,798 shares of the company's stock worth $5,532,000 after buying an additional 698 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company's stock.

Dyne Therapeutics Price Performance

Shares of DYN traded down $0.59 during midday trading on Monday, hitting $13.82. The stock had a trading volume of 7,057,183 shares, compared to its average volume of 1,709,244. Dyne Therapeutics, Inc. has a 1 year low of $6.36 and a 1 year high of $47.45. The firm has a market cap of $1.57 billion, a PE ratio of -3.88 and a beta of 1.16. The stock's 50 day moving average is $11.33 and its 200 day moving average is $14.89.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.17). As a group, equities research analysts expect that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Analysts Set New Price Targets

DYN has been the topic of several research analyst reports. Raymond James initiated coverage on shares of Dyne Therapeutics in a research note on Wednesday, June 11th. They issued an "outperform" rating and a $37.00 price target on the stock. HC Wainwright decreased their target price on Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Piper Sandler decreased their target price on Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. Scotiabank assumed coverage on Dyne Therapeutics in a report on Friday, March 7th. They set a "sector outperform" rating and a $50.00 price objective on the stock. Finally, BMO Capital Markets assumed coverage on Dyne Therapeutics in a report on Wednesday, March 12th. They set an "outperform" rating and a $50.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Dyne Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $44.93.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.